FRONTIERS OF SCIENCE Prof. Ingunn Holen: Tumour cell dormancy in bone – role in breast cancer relapse

Prof. Ingunn Holen, Department of Oncology and Metabolism, University of Sheffield, UK
Tumour cell dormancy in bone – role in breast cancer relapse

Ingunn Holen is Professor of Bone Oncology and senior team leader in the Department of Oncology and Metabolism, and science lead for the Sheffield Experimental Cancer Medicine Centre. She has more than 20 years of experience in working in advanced breast cancer, in particular in the context of translational studies in metastatic bone disease.
Ingunn Holen obtained her PhD from the University of Oslo in 1995 and then moved to the University of Sheffield, UK, to take up a post doc position in bone pharmacology. In 2001 she was recruited by Prof. Robert Coleman (Weston Park Hospital, Sheffield) to establish a Bone Oncology Laboratory Research Team, initially focusing on the potential of combining bone-targeted agents with chemotherapy to treat bone metastasis.

Currently, research in the Holen team is focused on elucidating the mechanisms underlying tumour cell spread to the skeleton, in particular how disseminated tumour cells interact with different components of the bone microenvironment. This is combined with the development of new therapeutic approaches in advanced breast and prostate cancer. The Holen team has established a range of in vitro and complex in vivo models for studies of tumour growth in bone, and work closely with clinical colleagues on translational research projects.
Terhi Jokilehto